ロード中...
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...
保存先:
| 出版年: | Med Oncol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5366170/ https://ncbi.nlm.nih.gov/pubmed/28343336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0928-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|